solute carrier organic anion transporter family member 1C1Genealiases: OATP-F · OATP-RP5 · OATP1 · OATP14 · OATP1C1 · OATPF
Q-omics provides the consensus-scored SLCO1C1 profile across patient tissues and cancer cell-line models. SLCO1C1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLCO1C1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SLCO1C1 RNA expression shows 16,404 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where SLCO1C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLCO1C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLCO1C1 survival associations across molecular data types. SLCO1C1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLCO1C1 RNA expression–survival associations across cancer types. High SLCO1C1 expression shows unfavorable associations in KIRP, BLCA and UVM, but favorable associations in KIRC, THCA and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLCO1C1 RNA expression.
This table summarizes SLCO1C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLCO1C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLCO1C1 shows lower tumor expression in COAD, KIRP, BRCA and LUSC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher SLCO1C1 RNA expression in tumor versus normal tissue (log2 FC = +0.849, t-test p < 0.001).
This table shows molecular features associated with SLCO1C1 in patient tissues and cancer cell lines. In patient samples, SLCO1C1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLCO1C1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
